KOSDAQElectrical Equipment149980

Hironic

₩4,000▲ 2.43%2026-11-18 close
Market Cap
₩68.8B
Turnover
₩24,748,150
Volume
6.3K
Shares out.
17.2M
PER
12.5×
PBR
0.9×
EPS
₩310
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Hironic: Recurring Sales Growth Meets an Audit Overhang

Hironic returned to operating profit in 2025 and has kept posting quarterly operating profit through the third quarter of 2026, with a model in which device sales feed recurring consumable revenue. Whether the audit qualification tied to inventory valuation has been fully resolved remains a point to check in the latest periodic filings.

  1. 1

    On August 14, 2026 the company said first-half consolidated revenue was KRW 20.4 billion and operating profit KRW 2.6 billion, with revenue a half-year record and operating profit the highest in 11 years.

  2. 2

    According to an independent research report, consumable sales rose from KRW 8.4 billion in 2024 to KRW 11.2 billion in 2025 and reached KRW 5.8 billion in the first half of 2026.

  3. 3

    Press coverage in 2025 described the 2024 operating loss of KRW 4.76 billion and controlling-shareholder net loss of KRW 5.45 billion as partly temporary, reflecting conservative recognition of inventory valuation issues.

  4. 4

    The qualified audit opinion on the 2024 annual report carried into the 2025 half-year report, and the reported cure period ran to April 10, 2026.

  5. 5

    Shareholder returns in the first half of 2026 totaled KRW 31.7 billion, combining KRW 27.7 billion of treasury share cancellation with KRW 4.0 billion of quarterly dividends.

02

Business structure

Hironic, founded in December 2007, makes and exports skin-aesthetic devices, including HIFU-based DOUBLO series products, radiofrequency (RF) devices and needle-free drug injectors.

Its flagship V-RO LIFTING combines high-intensity focused ultrasound (HIFU) and RF, and cartridge replacements after device sales generate consumable revenue. MIGLOU, a 2.45 GHz microwave device, received Korean product approval from the Ministry of Food and Drug Safety (MFDS) in July 2026.

SYNERJET PRO, a needle-free drug delivery device, began supply to clinics in August 2026, and it received U.S. FDA clearances for electrosurgery in April 2026 and for percutaneous electrical stimulation in September 2026.

The company said its home-use device line posted first-half 2026 sales of KRW 4.2 billion, up 154% year on year. Japan sales rose 144% in the first half of 2026, led by its subsidiary Hironic Japan Co., Ltd.

Overseas sales are handled by Hironic directly, domestic sales by a wholly owned subsidiary and home-beauty business by a 99%-owned subsidiary, as described in 2025 press coverage.

In July 2026 the company signed an exclusive U.S. and Canada distribution agreement with Venus Concept for V-RO LIFTING and shipped initial volumes. Customers are mainly clinics and overseas distributors.

Segment revenue shares are not supported by figures here, so device sales and consumable flows are the more reliable lens.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩8.3B₩500M5.8%
2025Q4₩8.4B₩1.7B20.3%
2026Q1₩9.6B₩1.5B15.2%
2026Q2₩10.8B₩1.1B10.2%
2026Q3₩9.7B₩1.3B13.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩27.6B₩3.6B₩2.9B13.0%5.0%15.0%
2023₩33.7B₩5.3B₩8.2B15.6%11.4%9.2%
2024₩31.6B-₩4.8B-₩5.5B−15.0%−7.8%14.6%
2025₩32.1B₩4.1B₩3.2B12.8%5.0%12.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed annual basis, revenue was KRW 27.6 billion in 2022, KRW 33.7 billion in 2023 (up 22.4% year on year), KRW 31.6 billion in 2024 (down 6.2%) and KRW 32.1 billion in 2025 (up 1.4%), with 2023 the largest year of the 2022–2025 period.

Operating profit reached KRW 5.27 billion in 2023 (up 47.2%) at a 15.6% operating margin. In 2024 the company swung to an operating loss of KRW 4.76 billion, a -15.0% margin, and 2025 press coverage attributed part of the enlarged loss to inventory valuation issues recognized conservatively during the audit.

In 2025 operating profit returned to KRW 4.1 billion, a 12.8% margin.

Net income attributable to controlling shareholders was KRW 8.22 billion in 2023, a net loss of KRW 5.45 billion in 2024 and KRW 3.16 billion in 2025, while total net income including non-controlling interests was KRW 3.14 billion in 2025 and should be read separately.

Operating cash flow was KRW 4.5 billion in 2022, -KRW 1.14 billion in 2023, KRW 5.24 billion in 2024 and -KRW 88.09 million in 2025. Quarterly operating profit rose from KRW 483 million in the third quarter of 2025 to KRW 1.71 billion in the fourth quarter, up 253.7% from the prior quarter.

First-quarter 2026 revenue was KRW 9.59 billion with operating profit of KRW 1.45 billion, and second-quarter revenue was KRW 10.8 billion with operating profit of KRW 1.1 billion.

Third-quarter 2026 revenue was KRW 9.65 billion, down 10.6% from the prior quarter but up 16.3% year on year, while operating profit was KRW 1.32 billion, up 20.6% from the prior quarter and 174.5% year on year.

Controlling-shareholder net income for the quarter was KRW 821 million, up 86.7% year on year, following KRW 1.27 billion in the first quarter and KRW 783 million in the second. Over the latest four quarters, controlling-shareholder net income totaled KRW 4.91 billion.

The company said first-half 2026 revenue was a half-year record and operating profit the highest in 11 years. The reason the gap between operating profit and controlling-shareholder net income moves from quarter to quarter should be checked in the quarterly report footnotes.

05

Industry analysis

For Hironic, the key industry link is between device placements and recurring consumable sales. An independent research report put consumable sales up 33% from KRW 8.4 billion in 2024 to KRW 11.2 billion in 2025.

The same report estimated first-half 2026 device sales at 476 units, more than half of the 744 units sold in all of 2025, and noted that cartridges and nozzles see higher demand as device placements grow.

On the home-use side, the company says demand is rising for energy-based devices that bring clinic-style treatments into the home. Overseas, European sales rose 247% in the first half of 2025 while Asian sales fell in the same period, and in the first half of 2026 Japan sales grew 144%, which points to growth in Asia.

Competitively, Hironic's HIFU and RF lineup is compared with peers in the same sector classification, including WON Tech and Asterasys. Market share comparisons lack a numerical basis, so the comparison rests on product range and distribution networks.

The cycle position of the sector is hard to pin down, and whether consumables grow as a share of revenue is the key metric to watch.

06

Outlook

The company said it plans to expand sales of new products in the second half of 2026, citing wider domestic sales of MIGLOU and SYNERJET PRO and a stronger base of recurring consumable sales as devices reach more clinics.

Overseas, it held its first online global launch symposium on October 14–15, 2026, introducing two new products to about 120 people from distributors in 31 countries.

The company said it would use the event to tidy up supply agreements with overseas partners and widen sales countries in sequence as regulatory approvals arrive. In North America, the model relies on Venus Concept's direct sales organization and its clinic network to expand device installations and consumable sales.

An independent research house that published in August 2026 expected North American revenue to start being reflected from the third quarter. A separate independent research view published in October 2026 expected 2026 consolidated revenue and profit to rise from 2025.

How much of third-quarter 2026 revenue, which grew 16.3% year on year, came from North America should be checked against disclosed filings. The company said it would maintain its active shareholder return policy. The next checkpoints are the pace of new country approvals and the revenue mix in the 2026 annual report.

07

Valuation

PER
12.5×
PBR
0.9×
ROE
7.0%
EPS
₩310
BPS
₩4,465
Dividend per share
₩0

How the valuation reads depends on which earnings period serves as the denominator. The multiple based on 2025 full-year controlling-shareholder net income of KRW 3.16 billion differs from the multiple based on the latest four quarters' total of KRW 4.91 billion, even at the same share price.

The latter uses the larger denominator and therefore produces the lower multiple. 2024 was a net loss at the controlling-shareholder level, so that year's multiple is not a useful comparison. The price-to-book ratio sits below 1x, which means the shares trade at a discount to net asset value.

Total equity at the end of 2025 was KRW 63.5 billion, all of it attributable to controlling shareholders, with total liabilities of KRW 7.71 billion and a debt-to-equity ratio of 12.1%.

Quarterly dividends were introduced in the first half of 2026, but treasury share cancellation, at KRW 27.7 billion of the KRW 31.7 billion first-half return total, accounts for most of the payout, so dividend yield alone does not show the scale of returns.

When comparing with past multiple ranges, the loss years that produce no meaningful multiple and the change in earnings base since 2025 should both be considered.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Earnings recovery and half-year records

After returning to operating profit of KRW 4.1 billion in 2025, the company announced on August 14, 2026 that first-half consolidated revenue was KRW 20.4 billion and operating profit KRW 2.6 billion. It described revenue as a half-year record and operating profit as the highest in 11 years.

Third-quarter 2026 operating profit of KRW 1.32 billion, up 174.5% year on year, shows quarterly profits continuing after the turnaround.

Recurring consumable revenue

According to an independent research report, consumable sales grew from KRW 8.4 billion in 2024 to KRW 11.2 billion in 2025 and reached KRW 5.8 billion in the first half of 2026.

Because cartridges and nozzles need replacing as device placements increase, a larger installed base widens the foundation for repeat revenue. The same report estimated first-half 2026 device sales at 476 units, more than half of 2025's 744 units.

Overseas approvals and distribution expansion

SYNERJET PRO has secured U.S. FDA clearances for both electrosurgery and percutaneous electrical stimulation. The company holds an exclusive U.S. and Canada distribution agreement with Venus Concept, and first-half 2026 Japan sales rose 144%. About 120 distributor representatives from 31 countries joined the October 2026 online global launch symposium.

09

Bear factors

Track record of a past loss

In 2024 the company posted an operating loss of KRW 4.76 billion and a controlling-shareholder net loss of KRW 5.45 billion, with a -15.0% operating margin. 2025 press coverage said inventory valuation issues, conservatively recognized, enlarged the loss temporarily. That a single year could swing to a loss is a track record to weigh when judging earnings stability.

History of a qualified audit opinion

The 2024 annual report received a qualified opinion because the external auditor could not obtain sufficient audit evidence on inventory valuation. Press coverage noted that such a qualification is a ground for delisting, and the company pursued a re-audit to resolve it.

The 2025 half-year report carried the qualification forward, with the reported cure period ending April 10, 2026.

Quarterly earnings volatility

Third-quarter 2026 revenue of KRW 9.65 billion fell 10.6% from the prior quarter. Controlling-shareholder net income ran at KRW 1.27 billion in the first quarter, KRW 783 million in the second and KRW 821 million in the third, staying below the first-quarter level.

Operating cash flow was negative at -KRW 88.09 million in 2025, which also points to variability in cash generation.

10

Risk factors

Accounting and audit risk

The qualified opinion on the 2024 annual report and the inventory audit-evidence issue bear directly on listing requirements. The reported cure period ended April 10, 2026, and how the re-audit and subsequent opinions were resolved should be confirmed in the latest periodic filings. The audit opinion on the 2026 annual report is the next checkpoint.

Regulatory and overseas distribution risk

Overseas sales of the new products depend on approval timelines in each country. North American sales rely on Venus Concept's direct sales organization and clinic network, so the partner's execution matters.

Even with fast growth in Japan and elsewhere, the business remains exposed to partner contract terms and local regulatory changes while the revenue base is still small.

Earnings volatility and consumable dependence

The 2024 swing to a loss and the quarterly ups and downs in 2026 show that earnings may not build in one direction. Consumable sales rise with installed devices, so slower device sales could also slow the growth of recurring revenue. The pace of newer businesses such as home-use devices is another variable that will shape the earnings path.

11

What to watch next

  1. From November 2026, as approvals arrive

    Whether approvals in individual countries lead to new sales markets for MIGLOU and SYNERJET PRO, and whether supply agreements with the 31-country distributor network are formalized. Expansion of sales countries is the check on overseas growth.

  2. End of March 2027

    The 2026 annual report, covering full-year revenue, operating margin, operating cash flow and the audit opinion. It is where the outcome of the re-audit after the 2024 qualification will be visible.

  3. May 15, 2027

    The first-quarter 2027 quarterly report, where the gap between operating profit and controlling-shareholder net income and any disclosure of North American revenue share can be checked.

  4. At each future disclosure

    Whether further treasury share cancellations or quarterly dividends are decided. Treasury share cancellation made up most of the first-half return, so whether that mix continues is the point to check.

12

Overall view

Hironic's 2026 can be summarized as a year in which earnings recovery and overseas approval expansion are advancing together. Full-year 2025 operating profit returned to KRW 4.1 billion, and quarterly operating profit has continued through the third quarter of 2026.

The structure in which consumable sales grow alongside device sales raises the repeatability of earnings. New-product approvals and the widening of sales to Japan, North America and 31 countries are cited as factors expanding the geographic footprint.

On the other side, the 2024 loss and the history of a qualified audit opinion tied to inventory remain matters to confirm in the latest periodic filings.

Third-quarter 2026 revenue fell from the prior quarter and controlling-shareholder net income has stayed below its first-quarter level, so disclosures explaining the gap between operating profit and net income carry weight.

Valuation reads differently depending on the earnings period used, so factual comparison is the appropriate frame. The next checkpoint is the audit opinion and full-year operating margin in the 2026 annual report, due by the end of March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. pharmnews.com
  2. view.asiae.co.kr
  3. m.news.nate.com
  4. thevaluenews.co.kr
  5. m.news.nate.com
  6. thevaluenews.co.kr
  7. m.news.nate.com
  8. m.news.nate.com
  9. thebell.co.kr
  10. m.beyondpost.co.kr
  11. view.asiae.co.kr
  12. view.asiae.co.kr
  13. newstopkorea.com
  14. newspim.com
  15. fnnews.com
  16. newspim.com
  17. view.asiae.co.kr
  18. mt.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis